France's Synerlab buys Alcalá Pharma

, , ,
Integral service around a transaction
BY : Diego GutiérrezNovember Tue, 2015
If a week ago we told you that Spanish biotechnologies were going public on the MAB, this week it is the turn of crowdfunding and the purchase of companies in the biotechnology sector.

logic-fin template

France's Synerlab buys Spain's Alcalá Farma.

The purchase has been made through the Frances Fund. Ardian to which the biotech company SynerlabThe 21 Partners group, which like Ardian is a shareholder in Synerlab, has also participated in the financing of the acquisition.

Alcalá Farma specialises in the development of proprietary formulations, which account for around 40% of its total sales, valued at €25M, and are the key lever for its future growth.

Its portfolio includes a wide range of finished dosage forms, such as injectable, oral or topical products.

The purchase will allow Synerlab, which already has 5 plants in France, to start expanding in the European market, first entering Spain. In addition to a broad and complementary product portfolio, with a strong presence of soft gelatin capsules and sticks.

With an average annual growth of around 8%, Synerlab is benefiting from the trend of pharmaceutical groups increasingly outsourcing their manufacturing activities and repatriating production to Europe for better quality control, as well as from the growing demand for generics.

Mint Labs and health Search seek funding from Capital cell

Health Startups Mint Labs and Health Search have decided to opt for crowdfunding to get funding and have done so on the Capital cell platform.

Mint Labs is a solution for early prediction of mental illnesses, which are often difficult to diagnose.

It can do this thanks to a cloud-based platform for the analysis and quantification of 3D data without the need to invest in data processing, hardware or software. This platform, which they call CloudN, can not only take images but can also receive medical images acquired in clinical and pre-clinical trials from pharmaceutical companies, hospitals or imaging centres.

So far the company has raised €62,175 and still has 21 days left to reach its target of €150,000.00.

HealthSearch is a pioneering company in services for the digitisation of the biomedical and pharma industry. Its multidisciplinary team combines experience both in the world of online marketing and in the medical industry itself, which allows it to offer immense added value to companies in the sector, mainly to independent professionals and SMEs in the biomedical sector, which at European level represents a market of 18 billion euros for 2017, in the digitisation of clinical processes.

So far the company has raised €10,616 of their €75,000 target and they still have 5i days to go.

cdti convenes international technology cooperation mission with the Indian Department of Biotechnology - DBT

The objective of the mission is to facilitate contacts between companies and entities of both countries in the Biotechnology and Life Sciences sector, identification of possible collaborations or ideas for R&D projects between entities of both countries, technical visits to facilities and centres of interest in India.

CDTI It also manages a cooperation programme with the Indian Department of Biotechnology through which competitive R&D projects between Spanish companies and Indian entities are promoted and financed.

The event will take place between 8 and 11 February 2016.

If you are looking for funding for the biotech sector, please contact us. Abra-Invest has a team of experts in alternative financing with many years of experience in the biotech sector. Call + 34 946424142 or fill in the contact form.

Other posts that may interest you

Biotech operations: Minoryx, Suanfarma, Ability Pharma and Oryzon Genomics

Biotech investment news September 2015: CaixaIpulse, Sanifit and Centauri Biotech

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?